Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2025
0mins
Source: PRnewswire
Special Cash Dividend Announcement: Aerovate Therapeutics has declared a special cash dividend of $69.6 million, approximately $2.40 per share, to be paid to stockholders of record as of April 25, 2025, contingent upon the closing of its merger with Jade Biosciences.
Merger Conditions and Voting: The payment of the cash dividend is dependent on the successful completion of the merger, which is expected to close around April 28, 2025, following approval from Aerovate's stockholders at a special meeting scheduled for April 16, 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
